Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Amos M. Cohen"'
Autor:
Daphna Levy, Ateret Davidovich, Shahar Zirkin, Yulia Frug, Amos M Cohen, Sara Shalom, Jeremy Don
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34736 (2012)
Potent survival effects have been ascribed to the serine/threonine kinase proto-oncogene PIM-2. Elevated levels of PIM-2 are associated with various malignancies. In human cells, a single Pim-2 transcript gives rise mainly to two protein isoforms (34
Externí odkaz:
https://doaj.org/article/614b875e681d4bd493d3c118a77ad8d8
Autor:
Amos M. Cohen, Luca Guerra, Cristina Messa, Léa Bernard, Gianpaolo Chiriano, Giovanni Giudici, Elena Sala, Luca Mologni, Sara Redaelli, Matthias Grube, Laura Antolini, Dries Deeren, Michael H. King, Alessandra Stasia, Rocco Piazza, Carlo Gambacorti Passerini, Lara Mussolin, Francesca Farina, Rainer Ordemann, Monica Ceccon, Michael Steurer
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7a792f9156f8f54cdd6dfdbde807394
http://hdl.handle.net/11577/3146199
http://hdl.handle.net/11577/3146199
Autor:
Heinz Huber, Peter Günczler, Amos M. Cohen, Heinz Ludwig, W. F. Jungi, Sándor Eckhardt, H. L. Seewann, Johannes Schüller, David Nachbaur, Elke Fritz, Hans-Jörg Senn, Franco Cavalli, Michael Micksche
Publikováno v:
European Journal of Cancer and Clinical Oncology. 27:S40-S45
The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance treatment improve treatment results in patients with multiple myeloma. Up to now 89 patients hav
Publikováno v:
Harefuah. 141(1)
Bleeding manifestations are common in patients with primary as well as secondary amyloidosis and have been attributed to different mechanical and metabolic causes. Factor X deficiency has been described in patients with primary amyloidosis, although
Autor:
Monica Ceccon, Michael Steurer, Léa Bernard, Gianpaolo Chiriano, Giovanni Giudici, Elena Sala, Alessandra Stasia, Luca Guerra, Luca Mologni, Dries Deeren, Matthias Grube, Rainer Ordemann, Rocco Piazza, Francesca Farina, Carlo Gambacorti-Passerini, Amos M. Cohen, Cristina Messa, Sara Redaelli, Michael H. King, Lara Mussolin
Publikováno v:
Blood. 122:368-368
In hematological disorders ALK expression is present in >50% of Anaplastic Large Cell Lymphomas (ALCL) as a result of a t(2;5)(p23;q35) translocation that causes the ALK gene on chromosome 2 to fuse with the NPM gene on chromosome 5. ALK + ALCL respo
Autor:
Yosef Dicken, Amos M. Cohen, Hanna Bessler, Ariela Arad, Daphna Levi-Hirsh, Jeremy Don, Drorit Merkel
Publikováno v:
Blood. 104:1916-1916
hPim-2 is a proto-oncogene that encodes a serine/threonine kinase and inhibits apoptosis by phosphorylation of BAD. We have shown that hPim is upregulated in human non-Hodgkin’s lymphomas (NHL) and in chronic lymphocytic leukemia (B-CLL) and its ce
Publikováno v:
Photochemistry and Photobiology. 68:584
Publikováno v:
Microscopy Research & Technique; Feb2004, Vol. 63 Issue 3, p155-158, 4p
Publikováno v:
Blood. 67:555-558
Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact
Publikováno v:
Blood. 68:920-926
Spectrin was shown previously to interact with phosphatidylserine and phosphatidylethanolamine, which are preferentially localized in the inner half of the membrane lipid bilayer, but this interaction is not well characterized. In the present study w